Patient visits are now complete in the final cohort of Phase 1b trial, consisting of Parkinson’s disease patients receiving 300 mg doses of HER-096 or placebo twice weekly over a four-week ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...

A new cancer vaccine targeting KRAS gene mutations shows promise in preventing pancreatic and colorectal cancer recurrence in ...

Clinical trial data management is growing increasingly complex, with inefficiencies driving up costs and delaying timelines.

H-D Feminine Health, announces it has initiated the first randomized, placebo-controlled, double-blinded Phase 3 clinical trial cleared to proceed by the U.S. Food and Drug Administration (FDA) to ...

Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE: MAIA) following quarterly ...

Data show that the cancer vaccine Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival in ...

In this Q&A, Rohit Nambisan, CEO of Lokavant, and Jonathan Crowther, head of predictive analytics, Pfizer, explore how AI is ...

Private equity house LDC has backed the expansion plans of a North West-headquartered business which is the UK’s largest site ...

Shore Capital Partners has formed PhaseWell Research, a Nashville-based clinical research site company. No financial terms were disclosed. In conjunction with the formation, Carsten Bick has been ...

Results from the Phase II COLLECTiVE202 trial (NCT05370885) demonstrated a statistically significant difference between VE202 ...